Get the Stockscreener App
2.41
2.03%
-0.05
After Hours:
2.41
In 8 Bio Inc stock is traded at $2.41, with a volume of 158.43K.
It is down -2.03% in the last 24 hours and up +11.57% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.46
Open:
$2.48
24h Volume:
158.43K
Relative Volume:
1.72
Market Cap:
$10.94M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-3.2133
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+6.64%
1M Performance:
+11.57%
6M Performance:
-46.41%
1Y Performance:
-64.33%
1-Day Range:
$2.32
$2.65
1-Week Range:
$2.2553
$2.65
52-Week Range:
$1.91
$16.70
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.41 | 11.17M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Bio, semiconductor, content firms to reboot Korea’s IPO market - The Korea Economic Daily Global Edition
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Wheeler Bio Appoints Jay Benson as Chief Operating Officer - PR Newswire
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Biotech Adicet Bio Issues New Employee Stock Options at $0.81 Under Special Inducement Plan - Stock Titan
Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Stock Offering at $2.50 - Stock Titan
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
180-Patient Phase 3 Trial: Nuvation Bio Tests IBTROZI for Early-Stage Lung Cancer Prevention - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com India
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewswire
Published on: 2025-09-27 16:04:15 - newser.com
What the charts say about Instil Bio Inc. todayBull Run & Weekly High Potential Stock Alerts - newser.com
What analysts say about INmune Bio Inc stockTechnical Breakout Signals & Free Daily Stock Hotspot Analysis - Early Times
Can Climb Bio Inc. recover in the next quarter2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Cabaletta Bio, Inc. $CABA Shares Purchased by Acadian Asset Management LLC - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August - MarketBeat
Layoff Tracker: Arvinas Downsizes by 15% After Punting Pfizer-Partnered Asset - BioSpace
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - BioSpace
Is KALA BIO Inc. stock ready for a breakoutEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Kalexo enters dyslipidemia fray with preclinical siRNA candidate - BioWorld MedTech
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots - Business Wire
100% Clinical Response: Palisade Bio's Novel UC Drug Shows Promise in Phase 1b with Zero Serious Side Effects - Stock Titan
Can Palisade Bio Inc. recover in the next quarter2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Passage Bio Inc. stock retracement – recovery analysisMarket Risk Report & Safe Entry Momentum Stock Tips - newser.com
Pattern recognition hints at Boundless Bio Inc. upsideJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Nuvation Bio: A Rare Gem In The Risky Biotech Space (NYSE:NUVB) - Seeking Alpha
Does Climb Bio Inc. show high probability of reboundJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Can GRI Bio Inc. recover in the next quarterGlobal Markets & High Accuracy Buy Signal Tips - newser.com
Will GRI Bio Inc. continue its uptrend2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
Novartis to acquire Tourmaline Bio for $1.4 billion - Reuters
Tourmaline Bio to Be Acquired by Novartis; $47.95M Termination Fee, Option Cashouts - Stock Titan
Remedium Bio Announces Strategic Collaboration With Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes - biospace.com
KALA BIO Soars 10.65% on Bullish Analyst Coverage - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Does Gossamer Bio Inc. align with a passive investing strategyJuly 2025 Analyst Calls & Weekly High Conviction Ideas - خودرو بانک
Palisade Bio Receives Health Canada Clearance for Phase 1b - GlobeNewswire
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
In 8 Bio Inc Stock (INAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCall Patrick | CHIEF FINANCIAL OFFICER |
Apr 30 '25 |
Option Exercise |
0.18 |
15,000 |
2,766 |
67,071 |
| Roemer Alan S. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
113,459 |
20,922 |
398,489 |
| Brandt Peter C. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
163,934 |
30,229 |
681,538 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):